177 related articles for article (PubMed ID: 37093316)
21. Identifying Diffuse Glioma Subtypes Based on Pathway Enrichment Evaluation.
Feng Q; Dong Z; Nie R; Wang X
Interdiscip Sci; 2024 Apr; ():. PubMed ID: 38637440
[TBL] [Abstract][Full Text] [Related]
22. Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery.
Zou Y; Xie J; Zheng S; Liu W; Tang Y; Tian W; Deng X; Wu L; Zhang Y; Wong CW; Tan D; Liu Q; Xie X
Int J Surg; 2022 Nov; 107():106936. PubMed ID: 36341760
[TBL] [Abstract][Full Text] [Related]
23. Subtyping of Human Papillomavirus-Positive Cervical Cancers Based on the Expression Profiles of 50 Genes.
Zhu X; Li S; Luo J; Ying X; Li Z; Wang Y; Zhang M; Zhang T; Jiang P; Wang X
Front Immunol; 2022; 13():801639. PubMed ID: 35126391
[TBL] [Abstract][Full Text] [Related]
24. Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women.
O'Meara T; Safonov A; Casadevall D; Qing T; Silber A; Killelea B; Hatzis C; Pusztai L
Breast Cancer Res Treat; 2019 May; 175(1):247-259. PubMed ID: 30725384
[TBL] [Abstract][Full Text] [Related]
25. Radiogenomic analysis reveals tumor heterogeneity of triple-negative breast cancer.
Jiang L; You C; Xiao Y; Wang H; Su GH; Xia BQ; Zheng RC; Zhang DD; Jiang YZ; Gu YJ; Shao ZM
Cell Rep Med; 2022 Jul; 3(7):100694. PubMed ID: 35858585
[TBL] [Abstract][Full Text] [Related]
26. A Case Series Exploration of Multi-Regional Expression Heterogeneity in Triple-Negative Breast Cancer Patients.
Xu Q; Kaur J; Wylie D; Mittal K; Li H; Kolachina R; Aleskandarany M; Toss MS; Green AR; Yang J; Yankeelov TE; Bhattarai S; Janssen EAM; Kong J; Rakha EA; Kowalski J; Aneja R
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362107
[TBL] [Abstract][Full Text] [Related]
27. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.
Xiao Y; Ma D; Zhao S; Suo C; Shi J; Xue MZ; Ruan M; Wang H; Zhao J; Li Q; Wang P; Shi L; Yang WT; Huang W; Hu X; Yu KD; Huang S; Bertucci F; Jiang YZ; Shao ZM;
Clin Cancer Res; 2019 Aug; 25(16):5002-5014. PubMed ID: 30837276
[TBL] [Abstract][Full Text] [Related]
28. Immune Profiles of Tumor Microenvironment and Clinical Prognosis among Women with Triple-Negative Breast Cancer.
Deng L; Lu D; Bai Y; Wang Y; Bu H; Zheng H
Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):1977-1985. PubMed ID: 31533938
[TBL] [Abstract][Full Text] [Related]
29. Unraveling Heterogeneity of Tumor Cells and Microenvironment and Its Clinical Implications for Triple Negative Breast Cancer.
Jiang K; Dong M; Li C; Sheng J
Front Oncol; 2021; 11():557477. PubMed ID: 33854958
[No Abstract] [Full Text] [Related]
30. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
Amara D; Wolf DM; van 't Veer L; Esserman L; Campbell M; Yau C
Breast Cancer Res Treat; 2017 Jan; 161(1):41-50. PubMed ID: 27815749
[TBL] [Abstract][Full Text] [Related]
31. Systemically Identifying Triple-Negative Breast Cancer Subtype-Specific Prognosis Signatures, Based on Single-Cell RNA-Seq Data.
Xing K; Zhang B; Wang Z; Zhang Y; Chai T; Geng J; Qin X; Chen XS; Zhang X; Xu C
Cells; 2023 Jan; 12(3):. PubMed ID: 36766710
[TBL] [Abstract][Full Text] [Related]
32. Integrated multi-cohorts for characterizing the immunogenomic landscape and predicting drug response in triple-negative breast cancer.
Su D; Chi M; Wang S; Di S; Zhang H; Lu Q; Yu Y; Xiong Y; Wei H; Lv Y; Zuo Y; Yang L
Brief Funct Genomics; 2022 May; 21(3):188-201. PubMed ID: 35348574
[TBL] [Abstract][Full Text] [Related]
33. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.
Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
Front Immunol; 2021; 12():749459. PubMed ID: 34603338
[TBL] [Abstract][Full Text] [Related]
34. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA
J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026
[TBL] [Abstract][Full Text] [Related]
35. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
[TBL] [Abstract][Full Text] [Related]
36. Identification of a prognosis‑associated signature associated with energy metabolism in triple‑negative breast cancer.
Li C; Li X; Li G; Sun L; Zhang W; Jiang J; Ge Q
Oncol Rep; 2020 Sep; 44(3):819-837. PubMed ID: 32582991
[TBL] [Abstract][Full Text] [Related]
37. Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq.
Karaayvaz M; Cristea S; Gillespie SM; Patel AP; Mylvaganam R; Luo CC; Specht MC; Bernstein BE; Michor F; Ellisen LW
Nat Commun; 2018 Sep; 9(1):3588. PubMed ID: 30181541
[TBL] [Abstract][Full Text] [Related]
38. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8.
Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N
Gene; 2021 Aug; 792():145728. PubMed ID: 34022297
[TBL] [Abstract][Full Text] [Related]
39. Genomic features of rapid versus late relapse in triple negative breast cancer.
Zhang Y; Asad S; Weber Z; Tallman D; Nock W; Wyse M; Bey JF; Dean KL; Adams EJ; Stockard S; Singh J; Winer EP; Lin NU; Jiang YZ; Ma D; Wang P; Shi L; Huang W; Shao ZM; Cherian M; Lustberg MB; Ramaswamy B; Sardesai S; VanDeusen J; Williams N; Wesolowski R; Obeng-Gyasi S; Sizemore GM; Sizemore ST; Verschraegen C; Stover DG
BMC Cancer; 2021 May; 21(1):568. PubMed ID: 34006255
[TBL] [Abstract][Full Text] [Related]
40. The molecular subtypes of triple negative breast cancer were defined and a ligand-receptor pair score model was constructed by comprehensive analysis of ligand-receptor pairs.
Pan W; Song K; Zhang Y; Yang C; Zhang Y; Ji F; Zhang J; Shi J; Wang K
Front Immunol; 2022; 13():982486. PubMed ID: 36119101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
